Published in Mol Imaging Biol on April 01, 2011
Reactive polymer enables efficient in vivo bioorthogonal chemistry. Proc Natl Acad Sci U S A (2012) 1.74
Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther (2012) 0.94
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther (2014) 0.89
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity (86)Y- or (177)Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging (2015) 0.78
Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. J Cancer Res Clin Oncol (2013) 0.78
Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. Sci Rep (2016) 0.78
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys (1991) 13.16
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med (2006) 2.15
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media Mol Imaging (2006) 1.89
Physical models and dose factors for use in internal dose assessment. Health Phys (2003) 1.85
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A (2000) 1.81
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med (2004) 1.81
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 1.77
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med (2007) 1.67
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood (2009) 1.66
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med (2007) 1.52
Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med (1998) 1.34
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res (2000) 1.30
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med (2003) 1.26
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med (1988) 1.16
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res (2006) 1.09
Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med (2006) 1.08
A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 1.05
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging (2007) 1.03
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem (2002) 1.03
Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys (2006) 1.02
Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med (2000) 0.99
MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J Nucl Med (2009) 0.95
Recent advances in pretargeted radioimmunotherapy. Curr Med Chem (2005) 0.94
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med (2009) 0.93
Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals. Bioconjug Chem (2010) 0.91
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med (1998) 0.91
Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol (1990) 0.90
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol (2009) 0.84
Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm (2005) 0.82
Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol (2007) 0.79
Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm (2000) 0.78
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol (2009) 6.15
Isolating and engineering human antibodies using yeast surface display. Nat Protoc (2006) 5.02
Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. Nature (2009) 4.98
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging (2003) 4.01
Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol (2006) 3.98
Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging (2010) 3.88
Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging (2002) 3.37
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol (2003) 3.34
The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol (2011) 3.24
Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Mol Imaging (2005) 3.19
Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01
14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol (2002) 2.97
Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol (2007) 2.92
Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol (2010) 2.85
Quantitation of brown adipose tissue perfusion in transgenic mice using near-infrared fluorescence imaging. Mol Imaging (2003) 2.68
Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat Methods (2008) 2.68
Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol (2011) 2.67
Size series of small indium arsenide-zinc selenide core-shell nanocrystals and their application to in vivo imaging. J Am Chem Soc (2006) 2.65
Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg (2005) 2.52
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat Biotechnol (2013) 2.44
Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol (2007) 2.38
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Compact cysteine-coated CdSe(ZnCdS) quantum dots for in vivo applications. J Am Chem Soc (2007) 2.35
Synthesis and in vivo fate of zwitterionic near-infrared fluorophores. Angew Chem Int Ed Engl (2011) 2.19
Three-dimensional surface profile intensity correction for spatially modulated imaging. J Biomed Opt (2009) 2.18
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
High-power, computer-controlled, light-emitting diode-based light sources for fluorescence imaging and image-guided surgery. Mol Imaging (2009) 2.15
In vivo optical imaging of pleural space drainage to lymph nodes of prognostic significance. Ann Surg Oncol (2004) 2.13
Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol (2007) 2.02
Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. Ann Surg Oncol (2006) 1.99
Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg (2005) 1.98
Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: a first in human experience. J Urol (2013) 1.97
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97
An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media Mol Imaging (2006) 1.89
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol (2006) 1.81
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Engineering InAs(x)P(1-x)/InP/ZnSe III-V alloyed core/shell quantum dots for the near-infrared. J Am Chem Soc (2005) 1.79
Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging (2010) 1.75
Near-infrared fluorescence-guided resection of colorectal liver metastases. Cancer (2013) 1.71
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
Sentinel lymph node mapping of the pleural space. Chest (2005) 1.67
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med (2007) 1.67
Tissue-like phantoms for near-infrared fluorescence imaging system assessment and the training of surgeons. J Biomed Opt (2006) 1.65
Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62
The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in perforator flap breast reconstruction. Plast Reconstr Surg (2010) 1.61
Real-time intraoperative assessment of the extrahepatic bile ducts in rats and pigs using invisible near-infrared fluorescent light. Surgery (2008) 1.60
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure (2013) 1.59
Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence. J Urol (2007) 1.57
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol (2009) 1.55
First-in-human pilot study of a spatial frequency domain oxygenation imaging system. J Biomed Opt (2011) 1.50
Structured illumination enhances resolution and contrast in thick tissue fluorescence imaging. J Biomed Opt (2010) 1.49
Near-infrared fluorescence imaging of microcalcification in an animal model of breast cancer. Acad Radiol (2003) 1.49
Intraoperative near-infrared fluorescence imaging in perforator flap reconstruction: current research and early clinical experience. J Reconstr Microsurg (2009) 1.46
Real-time intraoperative near-infrared fluorescence angiography for perforator identification and flap design. Plast Reconstr Surg (2009) 1.46
Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.46
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Real-time intra-operative near-infrared fluorescence identification of the extrahepatic bile ducts using clinically available contrast agents. Surgery (2010) 1.45
Quantitative assessment of perfusion and vascular compromise in perforator flaps using a near-infrared fluorescence-guided imaging system. Plast Reconstr Surg (2009) 1.44
Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients. Breast Cancer Res Treat (2011) 1.43
Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol (2004) 1.43
Lymphatic drainage of the peritoneal space: a pattern dependent on bowel lymphatics. Ann Surg Oncol (2007) 1.41
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods (2004) 1.39
Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe. J Am Chem Soc (2008) 1.38
Wavelength optimization for rapid chromophore mapping using spatial frequency domain imaging. J Biomed Opt (2011) 1.36
High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci U S A (2009) 1.35
Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem (2009) 1.33
Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res Treat (2013) 1.33
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther (2008) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
Nerve-highlighting fluorescent contrast agents for image-guided surgery. Mol Imaging (2011) 1.31
Synthesis of conjugatable bisphosphonates for molecular imaging of large animals. Angew Chem Int Ed Engl (2007) 1.29
Real-time, near-infrared, fluorescence-guided identification of the ureters using methylene blue. Surgery (2010) 1.29
Real-time assessment of cardiac perfusion, coronary angiography, and acute intravascular thrombi using dual-channel near-infrared fluorescence imaging. J Thorac Cardiovasc Surg (2009) 1.29
Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel (2004) 1.29
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation (2006) 1.28
A33 antigen displays persistent surface expression. Cancer Immunol Immunother (2008) 1.26
Engineering antibody affinity by yeast surface display. Methods Enzymol (2004) 1.26
Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol (2012) 1.26
Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using invisible near-infrared fluorescence light. Ann Surg Oncol (2010) 1.24
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res (2008) 1.24
Image-guided perforator flap design using invisible near-infrared light and validation with x-ray angiography. Ann Plast Surg (2009) 1.23
Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. Chem Biol (2007) 1.23
Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother (2008) 1.23
Near-infrared fluorescence imaging of liver metastases in rats using indocyanine green. J Surg Res (2011) 1.23
Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. Biotechnol Bioeng (2009) 1.23
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 1.23
Optimization of near-infrared fluorescent sentinel lymph node mapping in cervical cancer patients. Int J Gynecol Cancer (2011) 1.22
Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure (2006) 1.18